Full-Time
Associate Technical Consultant
Entry-Level Consulting, Life Sciences
Updated on 8/21/2026
Veeva Systems
10,001+ employees
Cloud-based quality, regulatory, and claims management
Compensation Overview
€48k/yr
Berlin, Germany
Hybrid
Typically requires two to three office days per week and residence within a 45-minute to one-hour commute of the Berlin or Frankfurt office.
Bachelor's
 Consulting (1) |
|---|
Get referred to Veeva Systems
See people who can refer or advise you
- A Bachelor's degree in computer science or a related field with strong academic performance is required.
- Demonstrated experience in object-oriented programming is required.
- Excellent technical storytelling skills and the ability to explain technical architecture or decisions to customers are required.
- Strong critical thinking skills and a proven track record of academic performance are required.
- Willingness to travel up to 20–30% of the time is required.
- Candidates must be recent university graduates with no more than two years of postgraduate experience.
- Fluency in German at a professional level and English is required.
- Candidates must be legally authorized to work in the European Union.
- Work directly with customers and project teams, providing technical expertise on Veeva applications, the Vault Platform, application programming interfaces, and Java software development kit.
- Develop custom code, configure Veeva software, contribute to solution design under experienced technical and migration architects, and support content and data migration.
- Build cutting-edge tools used globally by the Veeva Services team.
- Experience with Python, Java, JavaScript, or Structured Query Language.
- Familiarity with cloud platforms such as Amazon Web Services or Microsoft Azure.
- Experience using artificial-intelligence-powered development tools or command-line interface assistants such as Claude Code or Gemini CLI.
Veeva Systems provides cloud-based software that helps consumer goods and chemical companies manage quality, regulatory compliance, and advertising claims. The platform works by connecting different departments—from the supply chain to marketing—to provide a single source of data that tracks a product's journey and ensures it meets safety standards. Unlike competitors that offer general business tools, Veeva specializes in navigating the highly complex regulations originally found in the life sciences sector and applies that specific expertise to other regulated industries. The company's goal is to help businesses bring safe, sustainable, and compliant products to market faster by providing end-to-end visibility and traceability.
Company Size
10,001+
Company Stage
IPO
Headquarters
Pleasanton, California
Founded
2007
Get referred to Veeva Systems
See people who can refer or advise you
Simplify's Take
What believers are saying
- Fiscal Q1 2027 revenue hit $882.9 million, up 16%, with subscription revenue up 15%.
- Eli Lilly became Veeva's 11th top-20 biopharma Vault CRM commitment on August 11.
- UCB's June 1 go-live proved Veeva Safety Suite scales across 14 million documents.
What critics are saying
- Salesforce still attacks CRM budgets; TD Cowen flagged Veeva customer relationship losses on June 2026.
- AI commoditization threatens pricing once Copli-style agents become standard across rivals.
- If Falcon MLR underdelivers, customers delay migration and preserve legacy review stacks through 2027.
What makes Veeva Systems unique
- Veeva owns life-sciences workflows end-to-end, from trials to quality, regulatory, and commercial execution.
- Lilly selected Vault CRM globally on August 11, 2026, validating enterprise trust.
- Veeva Falcon MLR and Veeva EHS deepen platform breadth inside regulated operations.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Parental leave
PTO
Free food
Health, dental, & vision insurance
Gym membership reimbursement
Growth & Insights and Company News
6 month growth
↑ 0%1 year growth
↑ 0%2 year growth
↑ 0%Veeva Vault CRM selected by Eli Lilly and Company. Aug 11, 2026, 07:03 ET PLEASANTON, Calif., Aug. 11, 2026 /PRNewswire/ - Veeva Systems (NYSE: VEEV) today announced that Eli Lilly and Company (Lilly) has selected Veeva Vault CRM globally. Vault CRM is part of the Vault CRM application suite, which forms the technological foundation for "Agentic Commercial" - the new sales model that uses AI to help more patients get the right medications. "We are very excited to expand our strategic collaboration with Veeva by transitioning to Vault CRM," said Giuseppe Firenze, Senior Vice President of U.S. HCP and Field Engagement Hub at Lilly. "Vault CRM will help Lilly make our breakthrough medications accessible to more patients." "Lilly develops medicines that improve the lives of people around the world," said Peter Gassner, CEO of Veeva. "We are proud to expand our strategic collaboration with Lilly as part of the global rollout of Vault CRM." Learn more about the Veeva Vault CRM suite, including the Agentic Call Report for generating commercial evidence, at veeva.com/crm. About Veeva Systems Veeva provides the industry cloud for life sciences with applications, agents, data, and consulting. Veeva is committed to innovation, product quality, and customer success, serving more than 1,500 customers, from the world's largest pharmaceutical companies to emerging biotech companies. As a Public Benefit Corporation, Veeva is dedicated to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit veeva.com. Forward-looking statements of Veeva This press release contains forward-looking statements regarding Veeva's products and services and the expected results or benefits from the use of our products and services. These statements are based on our current expectations. Actual results may differ materially from those described in this press release, and we undertake no obligation to update such statements. There are numerous risks that could potentially negatively affect our results, including the risks and uncertainties disclosed in our Form 10-Q for the fiscal quarter ended April 30, 2026 - available here (see pages 33 and 34 for a summary of risks that could affect our business) - as well as in our subsequent SEC filings, which you can access at sec.gov. Contact: Maria Scurry Veeva Systems [email protected] Meera Lakhani-Patel Veeva Systems, Europe [email protected]
Vulcan Value Partners added Veeva Systems to its All-Cap strategy in Q2 2026, describing the company as the dominant vertical market software system of record for the life sciences industry. The investment firm noted that Veeva's customers rely on its platform to run their entire business, from drug development and regulatory approval to manufacturing, selling, and marketing. Veeva grew revenue and EBIT by 16% and 24% respectively in 2025 and maintained strong momentum into 2026. Despite these results, the stock fell nearly 20% year-to-date through end-June, moving in sympathy with the broader application software sector. On 29 July 2026, Veeva shares closed at $207.91, giving it a market capitalisation of $33.77 billion. According to data, 62 hedge funds held Veeva at the end of Q1, down from 75 in the previous quarter.
IDDI joins Veeva CRO Partner Program to expand eClinical technology offerings for clinical trials. July 17, 2026. BRUSSELS; RALEIGH, N.C.; July. 16, 2026 - IDDI today announced it has joined the Veeva CRO Partner Program, further expanding its eClinical technology ecosystem to support sponsors running clinical trials of all sizes and complexities. As a leading provider of biometrics services, including biostatistics, data management, RTSM, and strategic consulting, IDDI is committed to helping sponsors select the technologies that best fit their protocol requirements and operational needs. Through this partnership, IDDI will expand the range of eClinical solutions available to its customers by adding Veeva Clinical Data applications, including Veeva EDC, Veeva DQS, Veeva eCOA, and Veeva RTSM. By combining scientific expertise with advanced technology solutions, IDDI helps sponsors build efficient, scalable clinical trial strategies that support high-quality data collection, streamlined study execution, and successful clinical outcomes. "Sponsors need the flexibility to build clinical technology ecosystems that support their unique study requirements," said Tara Kervin, Chief Operating Officer at IDDI. "By joining the Veeva CRO Partner Program, we are expanding our eClinical technology portfolio with Veeva's EDC, DQS, eCOA, and RTSM solutions. Together, we can better align technology with protocol design, giving sponsors greater choice while helping them execute studies more efficiently and confidently." The partnership reflects a shared commitment to providing life sciences organizations with modern, connected solutions that support efficient trial execution and enable teams to manage increasingly complex studies with confidence. About IDDI IDDI is a trusted clinical data science partner. With 35+ years of research-driven experience, IDDI Inc. combine therapeutic expertise, biostatistical leadership, and regulatory insight to mitigate risk from design to registration and beyond. IDDI Inc. deliver uncompromising excellence in biostatistics, strategic consulting, clinical data management, IDMCs, and supporting eClinical technologies, because when every data point represents a patient, perfection is the only option.
Stifel has reiterated its Buy rating and $230 price target on Veeva Systems following the company's acquisition of Copli, an agentic medical, legal and regulatory solutions firm. Veeva rebranded the acquisition as Veeva Falcon MLR, claiming the solution can eliminate 70% or more of manual MLR labour within five years. The system conducts compliance checks on promotional and medical materials against approved labels and local regulations. Separately, Veeva launched Veeva EHS on 25 June, a new environmental, health and safety application within its Veeva Quality Cloud. Veeva Systems delivers industry cloud solutions for life sciences, offering software, AI, data and consulting services.
Veeva Systems has announced Veeva EHS, a new environmental, health and safety application within Veeva Quality Cloud. The solution enables manufacturing and testing sites to identify, manage and mitigate operational and environmental risks whilst ensuring global compliance readiness. Veeva EHS integrates directly with Veeva QMS and Veeva Training, allowing safety events to automatically trigger quality deviations and assign targeted retraining. This eliminates duplicate data entry and streamlines workflows across the entire EHS process. The application provides real-time insights into leading risk indicators and uses intelligent automation to improve site efficiency. Planned for early adopter availability in August 2026, Veeva EHS represents a significant advancement in how organisations manage environmental, health and safety responsibilities through a unified platform.